Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3-internal tandem duplication

Cancer Chemother Pharmacol. 2026 Jan 20;96(1):10. doi: 10.1007/s00280-025-04860-y.

Authors

Masakatsu Yanagimachi^{1

2}, Reiko Iwano³, Dai Keino⁴, Yu Kimizuka⁴, Daisuke Kurita⁴, Akiko Hayashi⁴, Naoyuki Miyagawa⁴, Tomoko Yokosuka⁴, Satoshi Hamanoue⁴, Fuminori Iwasaki⁴, Hiroaki Goto^{4

3}

Affiliations

¹ Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan. yanagimachi.0c40k@kanagawa-pho.jp.
² Clinical Research Institute, Kanagawa Children's Medical Center, Yokohama, Japan. yanagimachi.0c40k@kanagawa-pho.jp.
³ Clinical Research Institute, Kanagawa Children's Medical Center, Yokohama, Japan.
⁴ Division of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.

PMID: 41554949
DOI: 10.1007/s00280-025-04860-y

No abstract available

Keywords: Acute myeloid leukemia; FLT3–internal tandem duplication; Gilteritinib; Maintenance therapy; Pediatric; Therapeutic drug monitoring.